SAM #NOI-OD-27-000001

NIH Clinical Center radiopharmaceuticals for patient care

The NIH Clinical Center plans to obtain FDA-approved radiopharmaceuticals for patient care through its Nuclear Medicine Division. - Government buyer: National Institutes of Health (NIH), NIH Clinical Center, Department of Radiology and Imaging Sciences, Nuclear Medicine Division. - Named supplier: CARDINAL HEALTH 414, LLC. The notice does not identify a separate product manufacturer or OEM. - Products requested: FDA-approved radiopharmaceuticals that emit gamma, positron, beta, and/or alpha radiation; quantities and part numbers are not specified. - Notable requirement: High-energy positron radiopharmaceuticals are to be provided using the supplier’s patented tungsten delivery system, which NIH says reduces radiation exposure and lifting-related injury risk while meeting weight standards. - Estimated purchase ceiling: Not to exceed $900,000.

Description

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

This procurement is for a purchase order NTE $900,000 for FDA-approved radiopharmaceuticals for patient care by the Nuclear Medicine Division, Department of Radiology and Imaging Sciences at the NIH Clinical Center. CARDINAL HEALTH is a reputed and reliable FDA and US NRC vetted supplier of the required radiopharmaceuticals by the Clinical Center. Based on the past 25 years of contracting with this vendor, this vendor is the only acceptable vendor because they provide a comprehensive list of radiopharmaceuticals that uniquely meets the patient needs of the NIH Clinical Center. They are the only provider that can supply all radiopharmaceuticals that emit gamma, positrons, beta and/or alpha radiations. They also use a patented tungsten delivery system for dispensing the high energy positron radiopharmaceuticals. This system minimizes radiation exposure to the staff and the public, as well as meeting the weight standard that reduces the potential weightlifting injuries to the staff.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.500 This subpart authorizes the use of simplified procedures for the acquisition of supplies and services in amounts greater than the simplified acquisition threshold but not exceeding $9 million ($15 million for acquisitions as described in 13.500(c)), including options, if the contracting officer reasonably expects, based on the nature of the supplies or services sought, and on market research, that offers will include only commercial products or commercial services. Contracting officers may use any simplified acquisition procedure in this part, subject to any specific dollar limitation applicable to the particular procedure. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date.

Notice Type: Notice of Intent

NAICS Code: 325412

PSC Code: 3650

Posted Date: 10/13/2026

Close Date: 10/19/2026 12pm EST

End User IC: Clinical Center

POC Name: Ryssa Nix

Email Address: Ryssa.nix@nih.gov

View original listing